Canada reported its second case of rare blood clots linked to the AstraZeneca vaccine last April 17, just days after the first case.
The Canadian health ministry stated on Twitter that it has received a report of a patient in the province of Alberta who experienced “a very rare adverse event involving blood clots with low platelets” after receiving the AstraZeneca vaccine.
“The person has received treatment and is recovering,” the health ministry also stated.
During a teleconference, Alberta’s Chief Medical Officer Dr. Deena Hinshaw identified the patient as a man in his 60s.
Health authorities said that they “will continue to monitor the use of all COVID-19 vaccines closely and examine and assess any new safety concerns.”
Health authorities also continue to assert that the benefits of the AstraZeneca vaccine against COVID-19 outweigh the potential risks.
“I understand some Albertans have concerns about the safety of this vaccine,” Hinshaw stated on Twitter, adding that she continues to recommend AstraZeneca for those aged 55 and older.
“The global rate of this blood clot disorder has been estimated at only one case in 100,000 to 250,00 doses of vaccine. In contrast, those age 55 and older who get COVID-19 have a one in 500 chance of dying,” Hinshaw stated.
Hinshaw also encouraged Albertans “to get vaccinated as soon as they are able.”
“It is the best way to protect your health and the health of those around you,” Hinshaw said.
Hinshaw announced on April 18 that 1,147,048 doses of the vaccine have been administered across Alberta.
Canada reported its first blood clot case last April 13.